Anúncio
Anúncio

CSTL

CSTL logo

Castle Biosciences, Inc. Common Stock

39.34
USD
Patrocinado
-0.55
-1.38%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

39.36

+0.02
+0.05%

Relatórios de Lucros CSTL

Rácio de surpresa positiva

CSTL separação 20 de 26 últimas estimativas.

77%

Próximo Relatório

Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$77.23M
/
-$0.35
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-7.00%
/
+1650.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-10.52%
/
-206.06%

Castle Biosciences, Inc. Common Stock earnings per share and revenue

On 03 de nov. de 2025, CSTL reported earnings of -0.02 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 96.25% surprise. Revenue reached 83.04 milhão, compared to an expected 72.63 milhão, with a 14.33% difference. The market reacted with a +21.70% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.35 USD, with revenue projected to reach 77.23 milhão USD, implying an aumentar of 1650.00% EPS, and diminuir of -7.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Castle Biosciences, Inc. Common Stock reported EPS of -$0.02, beating estimates by 96.25%, and revenue of $83.04M, 14.33% above expectations.
The stock price moved up 21.7%, changed from $25.99 before the earnings release to $31.63 the day after.
The next earning report is scheduled for 25 de fev. de 2026.
Based on 10 analistas, Castle Biosciences, Inc. Common Stock is expected to report EPS of -$0.35 and revenue of $77.23M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio